Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis

Arthritis and Rheumatism

Volumn 52, Issue 10, 2005, Pages 3160-3167

  Lohmander, L Stefan ^a   Brandt, Kenneth D ^b   Mazzuca, Steven A ^b   Katz, Barry P ^b   Larsson, Staffan ^a   Struglics, André ^a   Lane, Kathleen A ^b  

^a LUND UNIVERSITY   (Sweden)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PLACEBO; STROMELYSIN;

ARTICLE; BLOOD SAMPLING; CLINICAL OBSERVATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT CAVITY; JOINT LIMITATION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; DOXYCYCLINE; FEMALE; HUMANS; KNEE JOINT; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PREDICTIVE VALUE OF TESTS;

EID: 26844472527     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21345     Document Type: Article

References (36)

1. Brandt KD, Mazzuca SA, Conrozier T, Dacre JE, Peterfy CG, Prowedini D, et al. Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? [review]. J Rheumatol 2002;29:1308-20.
2. Poole AR. Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis [review]. Rheum Dis Clin North Am 2003;29:803-18.
3. Lohmander LS, Poole AR. Defining and validating the clinical role of biomarkers in osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, editors. Osteoarthritis. 2nd ed. Oxford: Oxford University Press; 2003. p. 468-77.
4. Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu M, et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 1999;42: 129-36.
5. Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
6. Iwase T, Hasegawa Y, Ishiguro N, Ito T, Iwasada S, Kitamura S, et al. Synovial fluid cartilage metabolism marker concentrations in osteonecrosis of the femoral head compared with osteoarthrosis of the hip. J Rheumatol 1998;25:527-31.
7. Green MJ, Smith J, Gough A, Devlin J, Astin P, Emery P. Serum MMP-3 and MMP-1 correlate with disease activity and predict progression of joint damage in early rheumatoid arthritis [abstract]. Arthritis Rheum 1999;42 Suppl 9:S173.
8. Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease: correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26:251-8.
9. Garnero P, Mazieres B, Gueguen A, Abbal M, Berdah L, Freiburghaus C, et al. Association of 10 molecular markers of bone, cartilage and synovium with disease activity and joint damage in hip osteoarthritis patients: the ECHODIAH cohort [abstract]. Arthritis Rheum 2003;48 Suppl 9:S291.
10. Mazzuca SA, Brandt KD, Dieppe PA, Doherty M, Katz BP, Lane KA. Effect of alignment of the medial tibial plateau and x-ray beam on apparent progression of osteoarthritis in the standing anteroposterior knee radiograph. Arthritis Rheum 2001;44: 1786-94.
11. Brandt KD, Mazzuca SA, Katz BP, Lane KA, and the OA-Doxycycline Study Group. Doxycycline slows the rate of joint space narrowing in patients with knee osteoarthritis [abstract]. Arthritis Rheum 2003;48:3652.
12. Brandt KD, Mazzuca SA, Katz BP, Lane KA, and the OA-Doxycycline Study Group. The disease-modifying effect of doxycycline includes symptomatic benefit for patients with knee osteoarthritis [abstract]. Arthritis Rheum 2003;48:3653.
13. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Ann Rheum Dis 1957;16:494-502.
14. Mazzuca SA, Brandt KD, German NC, Buckwalter KA, Lane KA, Katz BP. Development of radiographic changes of osteoarthritis in the "Chingford knee" reflects progression of disease or non-standardised positioning of the joint rather than incident disease. Ann Rheum Dis 2003;62:1061-5.
15. National Health and Nutrition Examination Survey. II. Vital and health statistics anthropometric reference data and prevalence of overweight. DHHS;1987. Publ. #PHS 87-1688. p. 21-2.
16. Lequesne M. Quantitative measurements of joint space during progression of osteoarthritis: chondrometry. In: Kuettner K, Goldberg V, editors. Osteoarthritic disorders. Rosemont (IL): American Academy of Orthopedic Surgeons; 1995. p. 427-44.
17. Buckland-Wright JC, Macfarlane DG, Williams SA, Ward RJ. Accuracy and precision of joint space width measurements in standard and macroradiographs of osteoarthritic knees. Ann Rheum Dis 1995;54:872-80.
18. Walakovits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 1992;35:35-42.
19. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Serum levels of collagenase, stromelysin-1, and TIMP-1: age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994;37:1774-83.
20. Sharif M, Kirwan JR, Elson CI, Granell R, Clarke S. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum oligomeric matrix protein levels over five years. Arthritis Rheum 2004;50:2479-88.
21. Mazzuca SA, Brandt KB, Buckwalter KA. Detection of radiographic joint space narrowing in subjects with knee osteoarthritis: longitudinal comparison of the metatarsophalangeal and semiflexed anteroposterior view. Arthritis Rheum 2003;48:385-90.
22. Mazzuca SA, Brandt KD, Buckwalter KA, Lane KA, Katz BP. Knee pain reduces joint space width in conventional standing anteroposterior radiographs of osteoarthritic knees. Arthritis Rheum 2002;46:1223-7.
23. Vignon E, Piperno M, Hellio le Graverand MP, Mazzuca SA, Brandt KD, Mathieu P, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon Schuss views. Arthritis Rheum 2003;48:378-84.
24. Strand V, Kelman A. Outcome measures in osteoarthritis: randomized controlled trials [review]. Curr Rheumatol Rep 2004;6: 20-30.
25. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005;64:29-33.
26. Roos H, Dahlberg L, Hoerrner LA, Lark MW, Thonar EJ, Shinmei M, et al. Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise. Osteoarthritis Cartilage 1995;3:7-14.
27. Manicourt DH, Poilvache P, Nzeusseu A, van Egeren A, Devogelaer JP, Lenz ME, et al. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis Rheum 1999;42:1861-9.
28. Bobacz K, Maier R, Fialka C, Ekhart H, Woloszczuk W, Geyer G, et al. Is pro-matrix metalloproteinase-3 a marker for posttraumatic cartilage degradation? Osteoarthritis Cartilage 2003;11:665-72.
29. Naito K, Takahashi M, Kushida K, Suzuki M, Ohishi T, Miura M, et al. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis. Rheumatology (Oxford) 1999;38:510-5.
30. Takahashi M, Naito K, Abe M, Sawada T, Nagano A. Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther 2004;6:R208-12.
31. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
32. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002; 10:595-601.
33. Smith GN Jr, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996;39:235-44.
34. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996;93:14014-9.
35. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42:83-8.
36. Brandt KD. A pessimistic view of serologic markers for diagnosis and management of osteoarthritis: biochemical, immunologic and clinicopathologic barriers [review]. J Rheumatol Suppl 1989;18: 39-42.